WCN26-6587 Pegmolesatide Ameliorates CKD-Associated Cardiomyocyte Hypertrophy by Suppressing the EPOR/CD131-JAK2/STAT3 Pathway

Read full text Summarise with VIRAT
Authors: Xinyu Zhang, Li Zhu, Sufang Li, Tingru Lin, Liangying Gan, Li Zuo
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This study aimed to investigate the therapeutic effect and underlying mechanism of Pegmolesatide, a novel long-acting EPO receptor modulator, on cardiac hypertrophy associated with chronic kidney disease (CKD).

Fields of Study & Subjects

Erythropoietin and Anemia Treatment Cardiac Fibrosis and Remodeling Dialysis and Renal Disease Management

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
104254–104254
Publication date
25 March 2026
Language
EN